Equillium (EQ) Competitors $1.56 +0.42 (+36.84%) Closing price 04:00 PM EasternExtended Trading$1.50 -0.06 (-4.17%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EQ vs. GLSI, CRDF, DERM, CLLS, MEIP, ELDN, BDTX, LXEO, CABA, and FTLFShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Greenwich LifeSciences (GLSI), Cardiff Oncology (CRDF), Journey Medical (DERM), Cellectis (CLLS), MEI Pharma (MEIP), Eledon Pharmaceuticals (ELDN), Black Diamond Therapeutics (BDTX), Lexeo Therapeutics (LXEO), Cabaletta Bio (CABA), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Its Competitors Greenwich LifeSciences Cardiff Oncology Journey Medical Cellectis MEI Pharma Eledon Pharmaceuticals Black Diamond Therapeutics Lexeo Therapeutics Cabaletta Bio FitLife Brands Greenwich LifeSciences (NASDAQ:GLSI) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership. Which has stronger valuation & earnings, GLSI or EQ? Equillium has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$15.79M-$1.36-8.71Equillium$41.10M1.36-$8.07M-$0.56-2.79 Which has more risk & volatility, GLSI or EQ? Greenwich LifeSciences has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Equillium has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Do institutionals and insiders hold more shares of GLSI or EQ? 4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 51.7% of Greenwich LifeSciences shares are held by insiders. Comparatively, 31.6% of Equillium shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to GLSI or EQ? In the previous week, Greenwich LifeSciences had 7 more articles in the media than Equillium. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 2 mentions for Equillium. Greenwich LifeSciences' average media sentiment score of 0.38 beat Equillium's score of -0.56 indicating that Greenwich LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Is GLSI or EQ more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to Equillium's net margin of -19.62%. Equillium's return on equity of -139.56% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -700.90% -455.64% Equillium -19.62%-139.56%-90.56% Do analysts rate GLSI or EQ? Greenwich LifeSciences presently has a consensus target price of $42.00, suggesting a potential upside of 254.43%. Equillium has a consensus target price of $1.00, suggesting a potential downside of 35.90%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Greenwich LifeSciences is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Equillium 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryGreenwich LifeSciences beats Equillium on 8 of the 15 factors compared between the two stocks. Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.72M$3.11B$5.73B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-2.7920.4330.4625.16Price / Sales1.36238.53392.5787.62Price / CashN/A42.3737.0358.50Price / Book11.147.918.956.21Net Income-$8.07M-$54.72M$3.26B$265.38M7 Day Performance59.17%1.66%1.06%-1.13%1 Month Performance276.72%5.88%4.31%-0.71%1 Year Performance89.62%8.72%28.39%18.86% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium0.9109 of 5 stars$1.56+36.8%$1.00-35.9%+37.9%$55.72M$41.10M-2.7940Earnings ReportGLSIGreenwich LifeSciences1.4422 of 5 stars$12.01-1.3%$39.00+224.7%-13.6%$162.69MN/A-8.833News CoverageEarnings ReportAnalyst ForecastCRDFCardiff Oncology1.6216 of 5 stars$2.43-0.4%$10.10+315.6%-0.9%$162.32M$680K-2.7920Positive NewsDERMJourney Medical1.7193 of 5 stars$7.00+0.7%$10.83+54.8%+58.9%$161.91M$56.13M-18.4290Analyst RevisionCLLSCellectis3.3286 of 5 stars$2.90+1.8%$4.00+37.9%+22.6%$158.41M$56.30M-3.54290Short Interest ↓MEIPMEI Pharma1.7475 of 5 stars$4.88-0.2%N/A+47.6%$158.28M$65.30M-1.03100ELDNEledon Pharmaceuticals1.7079 of 5 stars$2.60-1.1%$10.00+284.6%-9.5%$157.49MN/A-2.2210Earnings ReportAnalyst DowngradeShort Interest ↑BDTXBlack Diamond Therapeutics3.3338 of 5 stars$2.75-0.4%$12.40+350.9%-54.8%$157.14MN/A11.9690Positive NewsLXEOLexeo Therapeutics2.3641 of 5 stars$4.92+4.2%$15.33+211.7%-60.6%$156.69M$650K-1.5158News CoverageEarnings ReportAnalyst RevisionCABACabaletta Bio2.1143 of 5 stars$1.77+3.5%$14.43+715.2%-67.7%$156.41MN/A-0.6550FTLFFitLife Brands4.1169 of 5 stars$16.75+0.8%$22.00+31.3%+8.4%$155.99M$64.47M19.9420Earnings Report Related Companies and Tools Related Companies Greenwich LifeSciences Competitors Cardiff Oncology Competitors Journey Medical Competitors Cellectis Competitors MEI Pharma Competitors Eledon Pharmaceuticals Competitors Black Diamond Therapeutics Competitors Lexeo Therapeutics Competitors Cabaletta Bio Competitors FitLife Brands Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EQ) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access